e-learning
resources
ERS Research Seminars
2004
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Disease-modifying genes in IPF
A. Xaubet Mir (Barcelona, Spain)
Source:
Research Seminar 2004 - Genotyping and Phenotyping of Diffuse Parenchymal Lung Diseases
Number:
14
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Xaubet Mir (Barcelona, Spain). Disease-modifying genes in IPF. Research Seminar 2004 - Genotyping and Phenotyping of Diffuse Parenchymal Lung Diseases
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
The new challenge of CTD-ILD: from basic science to clinical setting
Related content which might interest you:
Novel treatments for IPF
Source: International Congress 2014 – ERS/NEJM joint lunchtime session "The changing landscape of idiopathic pulmonary fibrosis (IPF)"
Year: 2014
Polymorphism of the genes of xenobiothics detoxification in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2004; 24: Suppl. 48, 536s
Year: 2004
Monitoring anti-inflammatory treatments in IPF and related disorders
Source: Annual Congress 2004 - Pathobiological methodologies in monitoring immunomodulatory treatments
Year: 2004
Tolerance and efficacy of antifibrotic treatments in IPF patients carriying telomere related gene mutations
Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases
Year: 2019
Does nintedanib have the same effect on FVC decline in patients with progressive fibrosing ILDs treated with DMARDs or glucocorticoids?
Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin?
Year: 2020
IPF
Source: Eur Respir Monogr 2017; 77: 199-223
Year: 2017
IPF
Source: Eur Respir Monogr 2017; 77: 58-65
Year: 2017
Efficacy and safety of etanercept in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2006; 28: Suppl. 50, 767s
Year: 2006
Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON
Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights
Year: 2017
Patterns of discontinuation in the long-term RECAP study of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights
Year: 2017
Concomitant medications and efficacy of nintedanib in patients with IPF
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil
Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia
Year: 2019
Late Breaking Abstract - The outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs
Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Year: 2021
Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of lung fibrosis: the SENSCIS trial
Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new?
Year: 2019
Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry
Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2020
Polymorphism of multidrug resistance gene (MDR1), interleukin 4 (IL4), IL13 genes in asthmatic patients and patients with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2008 - Advances in functional genomics of neoplastic and non-neoplastic lung diseases
Year: 2008
MUC5B genotype affects survival of patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment
Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Year: 2019
Expression of mRNA of selected inflammatory markers in BALf cells from patients with sarcoidosis and idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017
Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment
Source: Annual Congress 2009 - Sarcoidosis in review
Year: 2009
Promoters and inhibitors m-RNAs expression before and after treatment with interferon gamma-1b or colchicine in idiopathic pulmonary fibrosis: preliminary results
Source: Eur Respir J 2003; 22: Suppl. 45, 83s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept